← All Essa Pharma INC filings

Essa Pharma INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

EPIX
Essa Pharma INC
10-Q: ESSA Pharma Acquired by XenoTherapeutics, Ends Trials
ESSA Pharma Inc. has entered a definitive agreement to be acquired by XenoTherapeutics, Inc., signaling a strategic pivot following the termination of its masofaniten clinical trials.
EPIX
Essa Pharma INC
10-Q: ESSA Pharma Halts Clinical Trials, Initiates Strategic Review Amidst Disappointing Results
ESSA Pharma Inc. has terminated its clinical trials for masofaniten (EPI-7386) and initiated a strategic review to maximize shareholder value following disappointing interim results.
EPIX
Essa Pharma INC
10-Q: ESSA Pharma Halts Clinical Trials, Initiates Strategic Review Amidst Disappointing Results
ESSA Pharma Inc. has terminated its clinical trials for masofaniten and initiated a strategic review to maximize shareholder value after interim data revealed the drug's ineffectiveness compared to standard treatment.
EPIX
Essa Pharma INC
10-Q: ESSA Pharma Reports Q3 2024 Financial Results and Clinical Trial Updates
ESSA Pharma's Q3 2024 report details ongoing clinical trials for its prostate cancer drug, masofaniten, and its financial position.
EPIX
Essa Pharma INC
10-Q: ESSA Pharma Reports Q2 2024 Results, Advances Prostate Cancer Drug Development
ESSA Pharma reported its financial results for the quarter ended March 31, 2024, and provided updates on its clinical trials for its prostate cancer drug candidate, masofaniten.
EPIX
Essa Pharma INC
10-Q: ESSA Pharma Reports Q1 2024 Financial Results and Clinical Trial Updates
ESSA Pharma's Q1 2024 report details ongoing clinical trials for its prostate cancer drug, masofaniten, and provides a financial overview.